Novartis says 82 percent of leukemia patients in remission after CAR-T
(Reuters) - An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday.
(American Society of Clinical Oncology) In a federally funded, randomized phase III clinical trial performed by the Children's Oncology Group (COG), 90 percent of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84 percent were cancer free. These are the highest survival rates for these T-cell malignancies reported to date, according to the authors.
Conclusions: Although administrative data alone did not validly identify cancer-related events, administrative data in combination with chart collected EOIT dates was associated with excellent validity. The collection of EOIT dates by cancer registries would significantly expand the potential of administrative data linkage to assess cancer outcomes.
Authors: Simioni C, Zauli G, Martelli AM, Vitale M, Ultimo S, Milani D, Neri LM Abstract A decreased physical fitness has been reported in patients and survivors of acute lymphoblastic leukemia (ALL). This is influenced by the negative effects of the disease and by the treatments of childhood cancer. In the past, children were advised to recover in bed, and to take as much relax as possible. Nowadays, it is considered that too much immobility may result in a further decrease of physical fitness and functioning. Exercise training for ALL children has frequently been reported to improve physical fitness and the well-...
(American Society of Hematology) Adolescents and young adults with acute leukemia have a survival advantage if they receive treatment at a pediatric cancer center versus an adult center, according to a new study.
Pediatric Blood&Cancer, EarlyView.
Conditions: Neuroblastoma; Rhabdomyosarcoma; Ewing Sarcoma Family of Tumors; Osteosarcoma; Leukemia; Central Nervous System Tumor Intervention: Other: Sampling on blood, bone marrow and cerebrospinal fluid Sponsor: Institut Curie Not yet recruiting
On Aug 30, the US Food and Drug Administration (FDA) approved tisagenlecleucel (marketed by Novartis as Kymriah) as the first ever treatment that genetically modifies patients' own T cells. The approval is for children and young adults (up to 25 years of age) with relapsed or refractory acute B-cell lymphoblastic leukaemia —a leading cause of childhood cancer deaths. This treatment option is currently limited to 20 specially certified centres in the USA because of the complexity of the procedure and potentially serious side-effects.
Since its earliest conceptions by Emil Frei, Emil Freireich, and colleagues,1 the successful development of combination chemotherapy for young patients with acute lymphoblastic leukaemia has served as a sustained model for all other tumour types for all patients in the modern era of cancer therapy. With substantially improved outcomes with these multi-agent combination chemotherapy regimens from the 1960s to the present time in children with acute lymphoblastic leukaemia, more attention is now being placed on adolescents and young adults —an in-between group of patients with unique characteristics, patterns of adhere...
ConclusionsNeuropathic pain occurs in one in four adolescents and young adults receiving cancer therapy. Use of screening tools may increase the detection of neuropathic pain in adolescents and young adults receiving cancer therapy and could ultimately improve pain treatment.